Mitotic cdc2 Kinase and Alzheimer Neurodegeneration
Principal Investigator
Inez Vincent, PhD
Seattle Institute for Biomedical and Clinical Research
Seattle, WA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$80,000
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
A1999039
Summary
Dr. Vincent is exploring the hypothesis that some of the processes that cause cancer in dividing cells can also occur in non-dividing neurons. Because neurons cannot divide, these processes may lead to cell degeneration and cell death. She has already found that some of the proteins that are key to cell division and cell growth are present in the dying neurons of Alzheimer’s disease. These cell proteins are sometimes detectable in neurons even before the appearance of the lesions characteristic of AD. In this study, Dr. Vincent is testing whether introducing these cell cycle proteins into normal neurons will produce AD lesions. Once this question is answered, she will then attempt to determine if the known genetic mutations associated with AD affect the expression of the cell cycle proteins, and if so, how they do so.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD